CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 16 enrolled
Drug / intervention
BIOPIN-6 Active Implant with Naltrexone +1 morecombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06216132
NCT06216132Phase 1Completed

A Phase 1, Placebo-controlled, Single-Ascending-Dose, Study of BIOPIN 6 in Healthy Adults

Akyso Therapeutics, LLC·interventional·Posted Jan 22, 2024·Updated Apr 28, 2026

In Brief

A Phase 1 clinical trial evaluating BIOPIN-6 Active Implant with Naltrexone and BIOPIN-6 Placebo Implant for Opioid Use Disorder. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety and blood levels of a medicine, naltrexone, contained within an implant in healthy volunteers age 18 to 65 years. To do this, the implant containing the drug will be inserted under the skin, left in place for 3 months and then removed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 1CompletedFinished
202420252026
First PostedJan 22, 2024
Enrollment StartJun 24, 2024
Primary CompletionApr 18, 2025
Study CompletionApr 25, 2025
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 2.4 years ago

Interventions

BIOPIN-6 Active Implant with Naltrexonecombination

An extended release formulation of naltrexone implanted in the subcutaneous space.

BIOPIN-6 Placebo Implantdevice

The placebo will be an implant consisting of the poly-d-l Lactic Acid and polycaprolactone contained in BIOPIN 6 without naltrexone.